ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control SHP-2 is also associated with

SHP-2 is also associated with a variety of diseases

Effects of interleukin-2 in immunostimulation and immunosuppression

NDRG1 is a potent

apoptotic cells can be observed by flow cytometry by measuring changes in light scattering

Activity of the cytosolic enzyme is high in proliferating cells and peaks during the S-phase of the cell cycle

ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control SHP-2 is also associated withProduct Specification Species Human Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving